Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease

What will you learn from this webinar:

• CRISPR/Cas9 against familial AD caused by APP mutations
• CRISPR/Cas9 against familial AD caused by PSEN1 mutations
• Future perspectives on CRISPR/Cas9-based gene therapies for Alzheimer's disease

Webinar Programme:

• 15.00 Welcome and introduction by CRISPR Medicine News
• 15.05 Martin Ingelsson, Prof. | Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease
• 15.50 Q & A with Martin Ingelsson
• 16.25 Close by CRISPR Medicine News

Speaker | Title:

Martin Ingelsson​​​​​​​, Prof., University Health Network, Toronto, Canada | Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease

CMN interview​​​​​​​

Martin Ingelsson, MD, PhD, Clinician Scientist, Professor

Dr. Ingelsson earned his MD in 1995 and his PhD in 2001, both from the Karolinska Institute. He was Professor in Geriatrics at Uppsala University 2016-2021 and is now Professor at the Department of Medicine of University of Toronto, as well as Clinician Scientist at the University Health Network / Toronto Western Hospital. The aim of Dr. Ingelsson’s research is to increase our understanding of neurotoxic mechanisms in Alzheimer’s disease and Parkinson’s disease and to utilize this knowledge for the development of novel diagnostic and therapeutic applications for these disorders. Mainly, immunotherapy and gene therapy approaches against pathogenic protein species are evaluated on cell and animal models for the respective disorders. He has published close to 200 research papers, reviews and book chapters. His h-index is 69.

CMN interview